Home
Indictions and Orphan Designations
Healthcare Professionals
MEDIA NEWS
HOW TO ORDER
DSCSA
More
CALL 407-270-7790 or FAX 407-420-8001
CDC Video showing N.Fowleri
AK and miltefosine
4th Patient in the USA to survive the deadly Amoeba Parasite
Colombia: Leishmaniasis outbreak affects 80 in Norte de Santander
FDA Grants Profounda Orphan DD Approval for treatment of invasive candidiasis with Miltefosine
ID WEEK in SAN DIEGO
FDA Grants Profounda Inc. Orphan Drug Designation for treatment of Granulomatous Amebic Encephalitis
Five little-known diseases to watch out for in 2017
IDSA, ASTMH release leishmaniasis guidelines following increase in US cases
Deadly Parasitic Disease Finding Its Way to US Soil
Epidemiologic Correlates of Mortality among Symptomatic Visceral Leishmaniasis Cases: Findings from
Impavido® (miltefosine) is an FDA-approved treatment for cutaneous, mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO